Anti-LGI1 Encephalitis-Affected Neurons

Anti-LGI1 Encephalitis-Affected Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Anti-LGI1 Encephalitis-Affected Neurons</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Anti-LGI1</td>
</tr>
<tr>
<td class="label">FBDS</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Tumor association</td>
<td>Low (5-10%)</td>
</tr>
<tr>
<td class="label">CSF findings</td>
<td>Often normal</td>
</tr>
<tr>
<td class="label">Treatment response</td>
<td>Good</td>
</tr>
</table>

Anti-LGI1 encephalitis is an autoimmune encephalitis syndrome characterized by antibodies targeting leucine-rich glioma inactivated 1 (LGI1), a secreted neuronal protein that functions as an auxiliary subunit of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). Unlike many other autoimmune encephalitides, anti-LGI1 encephalitis is predominantly non-paraneoplastic and affects neurons primarily through functional disruption of synaptic signaling rather than direct immune-mediated cytotoxicity.

This page examines the populations of neurons affected in anti-LGI1 encephalitis, the molecular mechanisms of dysfunction, the characteristic seizure phenotypes, and the pathophysiological basis for cognitive impairment. Understanding these mechanisms provides insight into how disruption of a single synaptic protein can produce widespread network dysfunction and establishes a framework for understanding similar antigenic targets in other autoimmune encephalitides.

Anti-LGI1 Encephalitis-Affected Neurons

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Anti-LGI1 Encephalitis-Affected Neurons</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Anti-LGI1</td>
</tr>
<tr>
<td class="label">FBDS</td>
<td>Common</td>
</tr>
<tr>
<td class="label">Tumor association</td>
<td>Low (5-10%)</td>
</tr>
<tr>
<td class="label">CSF findings</td>
<td>Often normal</td>
</tr>
<tr>
<td class="label">Treatment response</td>
<td>Good</td>
</tr>
</table>

Anti-LGI1 encephalitis is an autoimmune encephalitis syndrome characterized by antibodies targeting leucine-rich glioma inactivated 1 (LGI1), a secreted neuronal protein that functions as an auxiliary subunit of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). Unlike many other autoimmune encephalitides, anti-LGI1 encephalitis is predominantly non-paraneoplastic and affects neurons primarily through functional disruption of synaptic signaling rather than direct immune-mediated cytotoxicity.

This page examines the populations of neurons affected in anti-LGI1 encephalitis, the molecular mechanisms of dysfunction, the characteristic seizure phenotypes, and the pathophysiological basis for cognitive impairment. Understanding these mechanisms provides insight into how disruption of a single synaptic protein can produce widespread network dysfunction and establishes a framework for understanding similar antigenic targets in other autoimmune encephalitides.

Molecular Pathophysiology

LGI1 Protein Biology

LGI1 (leucine-rich glioma inactivated 1) is a 60 kDa secreted neuronal protein encoded by the LGI1 gene located on chromosome 10q24. Despite its name (originally identified in glioma cells), LGI1 is expressed predominantly in the brain and plays critical roles in synaptic development and function. The protein belongs to the leucine-rich repeat (LRR) family and contains multiple protein-protein interaction domains that enable its role as a molecular scaffold at synaptic terminals.

The primary function of LGI1 is its interaction with postsynaptic AMPARs. LGI1 forms a ternary complex with the transmembrane AMPAR regulatory proteins (TARPs), particularly γ-2 (stargazin) and γ-8, which are essential for proper AMPAR trafficking, clustering, and function. This complex is critical for maintaining synaptic AMPAR density, particularly at hippocampal and cortical synapses [@lgi1_ampa2020]. LGI1 also interacts with presynaptic ADAM22 (a disintegrin and metalloproteinase 22), creating a trans-synaptic bridge that coordinates pre- and postsynaptic signaling.

Mechanisms of Antibody-Mediated Dysfunction

The antibodies in anti-LGI1 encephalitis are predominantly IgG4 subclass, which do not activate complement and instead exert their effects through functional blockade. The pathophysiological sequence unfolds as follows:

Affected Neuron Populations

Hippocampal CA1 Pyramidal Neurons

The CA1 pyramidal neurons are the most severely affected population in anti-LGI1 encephalitis. These neurons express high levels of LGI1 and rely heavily on LGI1-mediated AMPAR trafficking for synaptic integrity.

Electrophysiological Changes:

• Reduced amplitude of evoked excitatory postsynaptic currents (EPSCs)
• Accelerated synaptic depression during trains of stimuli
• Impaired long-term potentiation (LTP) at Schaffer collateral-CA1 synapses
• Enhanced inhibitory input from changed basket cell function

• Dendritic spine loss, particularly on oblique dendrites
• Altered spine morphology with reduced head diameter
• Progressive hippocampal atrophy detectable on MRI, particularly in the CA1 subfield [@hippocampal_atrophy2024]

Temporal Cortex Pyramidal Neurons

Layer 2/3 pyramidal neurons in the temporal neocortex are secondarily affected due to their dense reciprocal connections with the hippocampus and their own expression of LGI1-TARP-AMPAR complexes.

Key Features:

• Disruption of cortico-hippocampal feedforward inhibition
• Altered gamma oscillations (30-80 Hz) critical for memory consolidation
• Impaired integration of multimodal sensory information

Hypothalamic Neurons and FBDS Generation

The faciobrachial dystonic seizures (FBDS) characteristic of anti-LGI1 encephalitis arise from dysfunction in hypothalamic circuits, particularly involving the hypothalamus and its connections to the basal ganglia and brainstem.

Key Hypothalamic Regions:

• Tuberal nucleus: Altered output to the globus pallidus interna
• Mammillary bodies: Disrupted mammillothalamic tract signaling
• Arcuate nucleus: Autonomic dysregulation

Thalamic Relay Neurons

Thalamic nuclei, particularly the anterior thalamic nucleus (connected to the mammillary bodies) and medial dorsal nucleus (prefrontal relay), show altered activity patterns in anti-LGI1 encephalitis. This thalamic dysfunction contributes to:

• Disrupted thalamocortical oscillations
• Impaired attention and executive function
• Altered arousal and wakefulness regulation

Cerebellar Purkinje Cells

While less directly involved than limbic structures, cerebellar Purkinje cells express LGI1 and may be affected. Their dysfunction contributes to:

• Altered cerebellar-thalamo-cortical loops
• Potential ataxia or coordination difficulties in severe cases

Seizure Pathophysiology

Faciobrachial Dystonic Seizures (FBDS)

FBDS represent a distinctive seizure type almost exclusive to anti-LGI1 encephalitis. They are characterized by:

• Duration: 1-30 seconds (typically <10 seconds)
• Frequency: Often multiple per hour, up to 100+ per day
• Semiology: Brachial dystonia (arm extension/flexion), ipsilateral facial grimacing
• Consciousness: Typically preserved
• Trigger: Often precipitated by sudden sounds or surprises

Importantly, FBDS typically precede the development of full limbic encephalitis by weeks to months, providing a therapeutic window for early intervention [@fbds_clinical2022].

Temporal Lobe Seizures

Classic limbic seizures develop in most patients and arise from hippocampal and temporal cortical dysfunction:

Seizure Onset:

• Mesial temporal structures (hippocampus, amygdala)
• Secondary spread to lateral temporal cortex

• Oral (lip smacking, chewing, swallowing)
• Manual (fumbling, picking, rubbing)
• Perseveration of prior activity

• Prolonged confusion
• Anterograde amnesia (especially for events during the seizure)
• Todd's paralysis rare but possible

Secondary Generalization

Approximately 30-40% of patients experience secondary generalized tonic-clonic seizures. The propagation pathway typically involves:

Cognitive Impairment

Memory Dysfunction

The most prominent cognitive deficit in anti-LGI1 encephalitis is anterograde amnesia. The mechanistic basis includes:

• Encoding Failure: CA1 LTP impairment prevents formation of new memory traces
• Consolidation Disruption: Altered hippocampal-neocortical dialogue during sleep
• Retrieval Degradation: Even stored memories become less accessible

Executive Function

Prefrontal cortex dysfunction manifests as:

• Impaired set-shifting
• Reduced verbal fluency
• Poor planning and organization
• Disinhibition (in some cases)

Psychiatric Features

Up to 60% of patients develop psychiatric symptoms, including:

• Anxiety and fear (often as prodrome or accompanying FBDS)
• Personality changes
• Psychotic symptoms (less common than in anti-NMDA receptor encephalitis)

Neuroimaging Findings

MRI

Characteristic findings include:

• Hippocampal T2 hyperintensity: Often bilateral, mesial temporal
• Hippocampal atrophy: Progressive in untreated cases
• FLAIR hyperintensities: Temporal lobe white matter
• Cerebellar involvement (less common)

PET

FDG-PET typically shows:

• Hypermetabolism in medial temporal lobes (early stages)
• Hypometabolism in hippocampus and temporal cortex (chronic)
• Frontal hypometabolism with executive dysfunction

EEG

• Temporal lobe interictal epileptiform discharges (80%)
• Focal slowing over temporal regions
• Rarely, electrical status epilepticus during sleep (ESES) pattern

Treatment and Neuronal Recovery

Immunotherapy

First-line treatments target antibody production and remove circulating antibodies:

Neuronal Recovery

Neuronal recovery depends on several factors:

• Synaptic Plasticity: Remaining neurons can form new synaptic connections (sprouting)
• Antibody Clearance: As antibodies are removed, LGI1 function gradually recovers
• TARP Expression: New TARP synthesis can partially compensate

• Seizures often improve within weeks
• Cognitive recovery may take 6-24 months
• Residual deficits common in patients with delayed treatment

Prognostic Factors

Better outcomes associated with:

• Early treatment (within 4 weeks of symptom onset)
• Younger age
• Less hippocampal atrophy at baseline
• Absence of secondary generalization

• Treatment delay >3 months
• Initial refractory seizures
• Significant hippocampal atrophy
• Relapse episodes

Differential Diagnosis and Related Conditions

Other Anti-AMPAR Encephalitis

Anti-LGI1 encephalitis shares features with anti-AMPAR encephalitis (targeting GluA1/GluA2 subunits directly), but has distinct characteristics:

Anti-ADAM22 Encephalitis

LGI1 interacts with ADAM22; antibodies against ADAM22 itself produce a similar but distinct syndrome, often with more prominent movement disorders.

Genetic LGI1 Epilepsy

Autosomal dominant lateral temporal epilepsy (ADLTE) caused by LGI1 mutations provides insight into the consequences of chronic LGI1 haploinsufficiency. These patients have seizures beginning in adolescence but typically have less cognitive impairment than autoimmune cases.

Cross-Linking Connections

Related Cell Types

• [Hippocampal CA1 Pyramidal Neurons](/cell-types/hippocampal-ca1-pyramidal-neurons)
• [Temporal Cortex Pyramidal Neurons](/cell-types/cortical-pyramidal-l2-3)
• [Hypothalamic Orexin Neurons](/cell-types/hypothalamic-orexin-neurons)
• [Anti-AMPAR Encephalitis-Affected Neurons](/cell-types/anti-ampa-receptor-encephalitis-neurons)
• [Anti-NMDA Receptor Encephalitis-Affected Neurons](/cell-types/anti-nmda-receptor-encephalitis-neurons)

Related Proteins and Pathways

• [LGI1](/proteins/lgi1-protein)
• [AMPA Receptors](/proteins/ampa-receptors)
• [TARPs (γ-2, γ-8)tarp-gamma-8)
• [ADAM22](/proteins/adam22-protein)
• [Synaptic Plasticity Pathways](/mechanisms/synaptic-plasticity)

Related Diseases

• [Autoimmune Encephalitis](/diseases/autoimmune-encephalitis)
• [Temporal Lobe Epilepsy](/diseases/temporal-lobe-epilepsy)
• [Limbic Encephalitis](/diseases/limbic-encephalitis)
• [Faciobrachial Dystonic Seizures](/diseases/faciobrachial-dystonic-seizures)

References

External Links

• [Autoimmune Encephalitis - NINDS](https://www.ninds.nih.gov/health-information/disorders/autoimmune-encephalitis)
• [Lancet Neurology Review](https://doi.org/10.1016/S1474-4422(22)00107-0)
• [Allen Cell Type Atlas](https://portal.brain-map.org/)
• [BrainSpan Atlas](https://www.brainspan.org/)

Background

The study of anti-LGI1 encephalitis has evolved significantly since the condition was first characterized in 2010. Recognition that LGI1 is an AMPAR auxiliary protein rather than a classical receptor has transformed our understanding of the pathophysiology. The distinctive FBDS remain a clinical hallmark that should prompt early testing and treatment. Ongoing research focuses on biomarker development for treatment response prediction and understanding why some patients develop relapsing disease while others achieve complete remission.